Stichting Farma ter Verantwoording

Vrijdag 9 mei dient de inhoudelijke behandeling van deze rechtszaak tussen @StichtingFTV en "Rupsje Nooit Genoeg" @abbvie in de @rbankamsterdam, Parnassusweg 280, 1076 AV Amsterdam, van 09.30-12.30 uur. Openbare zitting, wel ID meenemen.

The Pharmaceutical Accountability Foundation is looking for a part-time Human Rights/Global Health researcher. See our job description at pharmaceuticalaccountability.org/2025/01/07/hum…

Part of the misunderstanding of drug pricing is the impact of pharmacy benefit managers. Prior to @costplusdrugs publishing our price list, there was not a benchmark to compare prices. They made sure that every contract was opaque and under an NDA For instance, Box, Tesla, Space X , and pretty much any self insured company can’t just come on @x and publish your PBM or insurance contract. As a result, the market is very inefficient for brand meds. Generics, which account for 90 pct of scripts on the USA are now efficient because of the price list we publish. In fact, generics are now cheaper here, than in most countries On branded meds, it’s a clusterfuck. I think Box now uses a pass through PBM so you can see your claims, and prices paid for meds. I know Tesla is working to do the same. Most CEOs have no idea they are getting ripped off. It goes like this. The PBMs have a subsidiary called a Rebate Aggregator. They buy their brand meds from the manufacturer at a significant discount. Say 80 pct. They then sell to their parent company, the PBM, at a lesser discount. Say 50 pct discount. The PBM then goes to the self insured, big companies and says they will pass on the entire rebate they get for each brand med, the full 50 pct But they don’t disclose that their subsidiary is keeping the 30 pct difference. That by definition inflates the price of brand meds. Enriching the PBMs But the bigger issue in terms of comparisons to other countries is that the manufacturers are only keeping 20 pct of the “retail price “. But it’s the full retail price that is usually (not always ) compared to the price other countries get. The true comparison should be the net price paid to the pharma manufacturers In most cases other countries will still pay less than the net price. But it’s not as dramatic as presented. As to what should we do? Transparency Every contract signed with anyone in the healthcare supply chain should be required to publish the entire contract. That will get us to an efficient market and IMO cut drug prices by at least 30 pct lower than today’s NET pricing because that will allow Box to compare their costs to Tesla, etc. The only reason you can’t is because the contracts both of you signed with your PBMs prevents it Go back to your PBMs and your Insurers ask them if you can publish your contracts. That’s how you change the game.

Proud that our court case against @abbvie on the excessive profits on blockbuster medicine #humira is discussed today in the prestigious medical journal @TheLancet @ferrybiedermann @StichtingFTV thelancet.com/action/showPdf…

De rechtszaak vanwege buitensporige medicijnprijzen zal begin 2025 plaatsvinden @StichtingFTV nporadio1.nl/fragmenten/nie…

@sabina Voogd van Farma ter Verantwoording in gesprek met @OmroepMAX @NPORadio1 @Nieuwsweekend over de buitensporige #winst van farmaceut @abbvie op het #geneesmiddel #humira in Nederland. nporadio1.nl/fragmenten/nie…

Het bestverkochte medicijn ter wereld is een zeldzaam goed medicijn tegen kanker. Maar door het intimiderende gedrag van farmagigant Merck, Sharp & Dohme (MSD) liggen overbehandeling en verspilling op de loer. Nieuw onderzoek ftm.nl/artikelen/make…

Amsterdamse rechtbank geeft groen licht voor rechtszaak tegen AbbVie: De rechtszaak die Stichting Farma ter Verantwoording (FtV) aanspande tegen het Amerikaanse farmaceutisch bedrijf Abbvie, is door de rechter ontvankelijk bevonden. dlvr.it/T9kngj

Vonnis van de Rechtbank Amsterdam in onze @StichtingFTV zaak tegen @Abbvie en @AbbVieUS over de €1,2 miljard excessieve winst op het medicijn #Humira in Nederland 2004-2018. uitspraken.rechtspraak.nl/details?id=ECL…

The actual court verdict (sorry, in Dutch) is found here: uitspraken.rechtspraak.nl/details?id=ECL… Maybe @AbbVie can provide an English translation, as the Amsterdam Court confirmed it had jurisdiction on @AbbVieUS ?

De Rechtbank Amsterdam heeft zojuist besloten dat Farma ter Verantwoording door mag naar de inhoudelijke behandeling van de @AbbVie #Humira zaak! farmaterverantwoording.nl/2024/07/17/per…

Amsterdam court allows the Pharmaceutical Accountability Foundation to proceed to the merits of its case against @abbvie. pharmaceuticalaccountability.org/2024/07/17/pre…

Het vonnis in de @StichtingFTV vs @Abbvie zaak over excessieve winst op #humira is door de rechtbank Amsterdam verschoven van 26 juni naar woensdag 17 juli. zie onze dagvaarding en AbbVie antwoord op farmaterverantwoording.nl/humira-adalimu…

the Amsterdam court has delayed the verdict (originally planned for 26 June) with 2-3 weeks

what a mistake by @msf please reconsider closing down @MSF_access.

Danka Stuijver in Medisch Contact: “De strijd van stichting Farma ter Verantwoording [tegen @abbvie] is een belangrijke stap … en zal, hopelijk, een precedent scheppen voor een eerlijker en transparanter medicijnbeleid in de toekomst. “ medischcontact.nl/opinie/blogs-c…

#PublicHealth #Netherlands @StichtingFTV v @abbvie excessive pricing case the keionline.org/40077 Arianna Schouten @KEI_DC #profiteers

Nu kosten de tekrten al > €200miljoen per jaar aan extra menskracht van apothekers om de patienten hun recht op toegang tot geneesmiddelen te realiseren.

Debat over tekorten in 2e kamer: medicijntekorten zitten in het generieke gedeelte van de €5,1 miljard extramurale markt. Alhoewel 80% van het volume aan gnm vormen zij slechts 25% van de kosten €1275 miljoen. Als die 10% duurder worden kost dat zorgverzekeraars €127miljoen.

Hoorzitting over dure geneesmiddelen in de Tweede Kamer op 27 mei begint met Wilbert Bannenberg, de voorzitter van @StichtingFTV tweedekamer.nl/nieuws/kamerni…